USPTO grants patent to Bellacure's drug-free treatment device for arthritis pain

The U.S. Patent and Trademark Office granted a patent today to Bellacure, Inc. for its knee pain treatment device, which was designed to allow the patient to reproducibly apply a therapeutic force that urges the femur and tibia apart on the affected side of the knee at an unmatched intensity level while maximizing force efficiency and minimizing weight (United States Patent 7,662,122).

The non-invasive, visually discreet Bellacure treatment device is worn against the skin and gives patients and physicians the ability to precisely adjust the amount of pain-relieving force applied to the osteoarthritic knee. The force application efficiency is achieved by using a cable tensioning system which creates a true 3-point-force system where nearly 100% of the force developed by the device contributes to the therapeutic effect which relieves OA knee pain. The cables automatically set to the proper initial length, matching the patient's unique anatomy exactly. Then the patient rotates the tensioning dial a certain number of times that is the same every time they don the device.

Bellacure congratulates its design team. "We are pleased that the USPTO has granted this patent protecting our unique knee pain treatment system. It is a testament to our R&D team's continuing effort to realize our company's mission, to bring the most effective, non-surgical and drug-free treatment option to those who suffer from arthritis pain," said Shane Sterling, Bellacure's Chief Executive Officer.